Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
202 stocks in the Americas match these filters · market cap, largest first. Clear filters
Data as of Aug 26, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| MRK | Merck & Co., Inc. | Oncology | $371.70B | $156.45 | −0.30% | +19.65% |
| AZN | AstraZeneca PLC | Oncology | $263.12B | $169.66 | −20.24% | +0.01% |
| A1ZN34.SA | AstraZeneca PLC | Oncology | $260.90B | 144.34 BRL | −24.19% | +0.85% |
| BMY | Bristol-Myers Squibb Company | Oncology |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $138.74B |
| $67.92 |
| −1.05% |
| +8.57% |
| RVMD | Revolution Medicines, Inc. | Oncology | $45.35B | $211.38 | −4.07% | +12.39% |
| ONC | BeOne Medicines AG | Oncology | $42.58B | $376.37 | −2.30% | +15.49% |
| BNTX | BioNTech SE | Oncology | $28.65B | $114.05 | −8.02% | +25.21% |
| INCY | Incyte Corporation | Oncology | $26.29B | $129.72 | −2.17% | +9.13% |
| GMAB | Genmab A/S | Oncology | $21.42B | $34.36 | −3.02% | +19.31% |
| EXEL | Exelixis, Inc. | Oncology | $14.05B | $56.72 | −1.48% | +1.63% |
| SMMT | Summit Therapeutics Inc. | Oncology | $10.66B | $13.36 | −55.54% | +1.95% |
| NUVL | Nuvalent Inc | Oncology | $9.79B | $123.96 | −0.02% | 0.00% |
| CGON | CG Oncology, Inc. | Oncology | $7.00B | $78.95 | −2.49% | +7.39% |
| E2XE34.SA | Exelixis, Inc. | Oncology | $6.61B | 137.40 BRL | −2.25% | −2.25% |
| LNTH | Lantheus Holdings, Inc. | Oncology | $6.58B | $100.87 | −9.82% | −6.63% |
| COGT | Cogent Biosciences, Inc. | Oncology | $6.39B | $36.80 | −15.85% | −9.00% |
| ERAS | Erasca, Inc. | Oncology | $6.16B | $17.76 | −26.85% | −5.88% |
| RLAY | Relay Therapeutics, Inc. | Oncology | $4.51B | $20.57 | −3.29% | +10.35% |
| ELVN | Enliven Therapeutics, Inc. | Oncology | $4.48B | $61.01 | −2.10% | +15.69% |
| CELC | Celcuity Inc. | Oncology | $4.44B | $92.27 | −38.90% | +12.16% |
| TNGX | Tango Therapeutics, Inc. | Oncology | $4.13B | $24.51 | −28.73% | −8.27% |
| IDYA | IDEAYA Biosciences, Inc. | Oncology | $4.10B | $42.48 | −0.47% | +15.53% |
| RCUS | Arcus Biosciences, Inc. | Oncology | $4.02B | $31.57 | −0.52% | +13.40% |
| TLX | Telix Pharmaceuticals Limited | Oncology | $3.96B | $11.68 | −7.30% | +17.03% |
| IMNM | Immunome, Inc. | Oncology | $3.34B | $29.39 | −2.25% | +30.14% |
| ZLAB | Zai Lab Limited | Oncology | $2.94B | $26.17 | −26.18% | +40.40% |
| SLS | SELLAS Life Sciences Group, Inc. | Oncology | $2.89B | $14.09 | −11.27% | +29.98% |
| NRIX | Nurix Therapeutics, Inc. | Oncology | $2.73B | $26.95 | −4.53% | +15.02% |
| NUVB | Nuvation Bio Inc. | Oncology | $2.49B | $7.10 | −27.18% | +6.61% |
| URGN | UroGen Pharma Ltd. | Oncology | $2.27B | $46.36 | −8.76% | +11.82% |
| XNCR | Xencor, Inc. Common Stock | Oncology | $2.18B | $29.30 | −4.25% | +47.53% |
| HCM | HUTCHMED (China) Limited | Oncology | $2.13B | $12.26 | −33.01% | +10.25% |
| NBTX | Nanobiotix S.A. | Oncology | $2.11B | $41.51 | −27.35% | +3.31% |
| NVCR | NovoCure Limited | Oncology | $2.05B | $17.62 | −17.86% | +3.46% |
| ZYME | Zymeworks Inc. | Oncology | $1.96B | $27.47 | −9.93% | +19.43% |
| IMCR | Immunocore Holdings plc | Oncology | $1.93B | $37.40 | −8.14% | +10.75% |
| DMRA | Damora Therapeutics, Inc. | Oncology | $1.89B | $30.62 | −20.10% | +4.01% |
| VIR | Vir Biotechnology, Inc. | Oncology | $1.81B | $10.71 | −8.15% | +21.70% |
| INBX | Inhibrx Biosciences, Inc. | Oncology | $1.81B | $122.72 | −20.97% | +48.84% |
| SNDX | Syndax Pharmaceuticals, Inc. | Oncology | $1.77B | $19.92 | −22.16% | −2.92% |
| BCAX | Bicara Therapeutics Inc. | Oncology | $1.63B | $24.58 | −20.68% | −11.61% |
| AAPG | Ascentage Pharma Group Internat | Oncology | $1.57B | $16.79 | −65.35% | −11.12% |
| AVBP | ArriVent BioPharma, Inc. | Oncology | $1.55B | $31.35 | −12.50% | +3.95% |
| REPL | Replimune Group, Inc. | Oncology | $1.49B | $15.80 | −0.57% | +83.08% |
| AKTS | Aktis Oncology, Inc. | Oncology | $1.48B | $26.69 | −21.94% | +10.24% |
| CGEM | Cullinan Therapeutics, Inc. | Oncology | $1.48B | $22.95 | −0.48% | +31.67% |
| ORIC | ORIC Pharmaceuticals, Inc. | Oncology | $1.40B | $13.83 | −7.37% | +15.06% |
| DRTS | Alpha Tau Medical Ltd. | Oncology | $1.36B | $14.70 | −2.13% | +20.39% |
| IMTX | Immatics N.V. | Oncology | $1.26B | $9.24 | −25.54% | +7.07% |
| GLUE | Monte Rosa Therapeutics, Inc. | Oncology | $1.24B | $14.56 | −43.50% | −35.46% |
| CRVS | Corvus Pharmaceuticals, Inc. | Oncology | $1.22B | $14.56 | −45.97% | +12.69% |
| JANX | Janux Therapeutics, Inc. | Oncology | $1.14B | $18.68 | −47.14% | +19.97% |
| KURA | Kura Oncology, Inc. | Oncology | $1.10B | $13.59 | −2.23% | +33.89% |
| CADL | Candel Therapeutics, Inc. | Oncology | $1.04B | $13.60 | −2.51% | +36.55% |
| GERN | Geron Corporation | Oncology | $995.83M | $1.55 | −22.89% | +4.73% |
| OLMA | Olema Pharmaceuticals, Inc. | Oncology | $954.60M | $10.91 | −69.91% | −9.16% |
| ANL | Adlai Nortye Ltd. | Oncology | $884.83M | $13.74 | −20.35% | +13.93% |
| RIGL | Rigel Pharmaceuticals, Inc. | Oncology | $864.97M | $46.75 | −10.51% | +25.03% |
| AURA | Aura Biosciences, Inc. | Oncology | $810.97M | $7.82 | −17.99% | +9.22% |
| NVCT | Nuvectis Pharma, Inc. | Oncology | $777.72M | $25.89 | −11.56% | +32.50% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.